Genzyme was down $3.59, or 5 percent, to $68.48. The annual cost of Genzyme's Gaucher disease drug, Cerezyme, at more than $300,000, has spurred a debate over the most effective dosage that will also reduce the medicine's expense. Genzyme shares are down 8 percent for the year.
Genzyme Corporation is a biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third biggest biotechnology company employing over 9,000 people around the world. At present, the company has approximately 80 locations in 40 countries. It includes 17 manufacturing facilities and 9 genetic testing laboratories. The company’s products are available in nearly 90 countries.
In 2006, Genzyme generated $3.2 billion in revenues with more than 25 products in the world’s markets. The company is also involved in philanthropic acts, donating $83 million in global product donations and $11 million in cash contributions in 2006.
In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for." Additionally in 2007, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the President of the United States to America’s leading innovators.
Rite Aid was down 10 cents, or 4.1 percent, to $2.36. The retail drugstore chain said it expects to record an income tax expense that may increase its fourth-quarter loss by $800 million to $1 billion, or by $1.11 to $1.38 a share. Rite Aid shares are down 15.4 percent for the year.
Rite Aid is a United States retailer and pharmacy chain, operating over 5,000 stores in 31 states and the District of Columbia. Rite Aid is the largest drugstore chain on the East Coast and the third largest drugstore chain in the U.S. The company is publicly traded on the New York Stock Exchange under the ticker RAD.
Rite Aid began in 1962 as a single store opened in Scranton, Pennsylvania called Thrif D Discount Center. After several years of growth, Rite Aid adopted its current name and debuted as a public company in 1968. Rite Aid is headquartered in Camp Hill, a suburb of Harrisburg, Pennsylvania.
One should expect a winter escalation of hostilities. We will definitely see it either in December or early next year. There is no reason for a break - only a small part of the mobilised has been deployed to the zone of the special operation yet